STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Gilead Provides Update on Phase 3 EVOKE-01 Study

Rhea-AI Summary
Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. The study evaluated Trodelvy vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. While Trodelvy showed a numerical improvement in overall survival, it did not reach statistical significance. The safety profile for Trodelvy was consistent with prior studies, and Gilead intends to explore potential pathways to understand its role in patients non-responsive to last prior anti-PD-(L)1 therapy. Despite this setback, Gilead remains confident in its ongoing Phase 3 EVOKE-03 study and has a broad clinical development program in lung cancer with domvanalimab, the first Fc-silent investigational anti-TIGIT antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.15%
Tags
clinical trial
-
News

Gilead Sciences with Emma's Story: Self-Advocacy in Breast Cancer

Rhea-AI Summary
Gilead Sciences announces a partnership with a leading biotech company to develop a new breast cancer treatment. The collaboration aims to address the unmet medical needs of younger breast cancer patients. The PR highlights the positive clinical trial results and the potential impact on Gilead's financial performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
News

Gilead Pays Tribute to Patient Advocacy Work: Cara’s Story

Rhea-AI Summary
Gilead Sciences (GILD) Honors Cancer Patient with Conference Room Naming
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
News

Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) has been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) for the third consecutive year. The company was also included on the Dow Jones Sustainability North America Index (DJSI North America). Gilead's ESG strategy aims to position the company as an employer of choice that delivers shareholder value in a sustainable, responsible manner. The rankings are based on Gilead's sustainability performance, highlighting the company's longstanding sustainable business practices and transparency on environmental, social, and governance (ESG) issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD) Announces FDA Approval for Yescarta Label Update Demonstrating Superior Overall Survival in Patients with Relapsed/Refractory Large B-cell Lymphoma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
fda approval
-
News

Gilead Sciences to Present at Upcoming Investor Conference

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) executives to speak at J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
News

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Rhea-AI Summary
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces positive in vitro results for investigational drugs opaganib and RHB-107 in combination with remdesivir, showing a distinct synergy in viral inhibition while maintaining cell viability. Opaganib and RHB-107 are expected to be effective against multiple viral targets, including COVID-19 and emerging viral variants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
News

Gilead Supports World Health Organization To Bolster Public Health in Bangladesh

Rhea-AI Summary
Gilead Sciences (GILD) celebrates the milestone announced by the World Health Organization, marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company has operations in more than 35 countries worldwide and is headquartered in Foster City, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
News

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced an exclusive licensing agreement with Compugen Ltd. (Nasdaq: CGEN) for a pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. The deal involves a $60 million upfront payment and $30 million milestone payment with a total deal value of up to $848 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.97%
Tags
none
News

Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas

Rhea-AI Summary
Kite, a Gilead Company (Nasdaq: GILD) announced data from follow-up analyses of three studies of Yescarta demonstrating the long-term survival potential for patients with relapsed or refractory non-Hodgkin lymphoma. The studies showed long-term survival benefits, durable response, and overall survival in patients with refractory large B-cell lymphoma, relapsed/refractory follicular lymphoma, and elderly patients. The studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY